SOS2 and hepatocellular carcinoma: Further, SOS2, as the target of sulfarotene, knockdown combined with sorafenib exhibited the lower IC50 values of 7.68 μM and 14.39 μM of the selected Hep3B-TRCs and PLC/PRF/5-TRCs after 48 h treatment compared with sorafenib alone treated for HCC TRCs, which is similar to the effect of sorafenib treated for HCC cell lines (Figure S15).